Toward understanding and exploiting tumor heterogeneity
Ash A Alizadeh, Victoria Aranda, Alberto Bardelli, Cedric Blanpain, Christoph Bock, Christine Borowski, Carlos Caldas, Andrea Califano, Michael Doherty, Markus Elsner, Manel Esteller, Rebecca Fitzgerald, Jan O Korbel, Peter Lichter, Christopher E Mason, Nicholas Navin, Dana Pe'er, Kornelia Polyak, Charles W M Roberts, Lillian Siu, Alexandra Snyder, Hannah Stower, Charles Swanton, Roel G W Verhaak, Jean C Zenklusen, Johannes Zuber, Jessica Zucman-Rossi, Ash A Alizadeh, Victoria Aranda, Alberto Bardelli, Cedric Blanpain, Christoph Bock, Christine Borowski, Carlos Caldas, Andrea Califano, Michael Doherty, Markus Elsner, Manel Esteller, Rebecca Fitzgerald, Jan O Korbel, Peter Lichter, Christopher E Mason, Nicholas Navin, Dana Pe'er, Kornelia Polyak, Charles W M Roberts, Lillian Siu, Alexandra Snyder, Hannah Stower, Charles Swanton, Roel G W Verhaak, Jean C Zenklusen, Johannes Zuber, Jessica Zucman-Rossi
Abstract
The extent of tumor heterogeneity is an emerging theme that researchers are only beginning to understand. How genetic and epigenetic heterogeneity affects tumor evolution and clinical progression is unknown. The precise nature of the environmental factors that influence this heterogeneity is also yet to be characterized. Nature Medicine, Nature Biotechnology and the Volkswagen Foundation organized a meeting focused on identifying the obstacles that need to be overcome to advance translational research in and tumor heterogeneity. Once these key questions were established, the attendees devised potential solutions. Their ideas are presented here.
Conflict of interest statement
COMPETING FINANCIAL INTERESTS
The authors declare competing financial interests: details are available in the online version of the paper.
Figures
Source: PubMed